secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001384101-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q4 revenue $140.6M (+19% YoY); GAAP net income $41.1M, generates $52.6M operating cash
--------------------------------------------------------------------------------

- Q4 total revenue $140.6M (+19% YoY); testing revenue $135.8M (+21%); total volume 48,019 tests (+16%).
- Decipher revenue $85.6M (+27%); Afirma revenue $47.9M (+16%); strong double-digit growth in both segments.
- GAAP net income $41.1M (29.3% margin); adjusted EBITDA $42.3M (30.1% margin); $52.6M operating cash flow.
- Full-year 2025 revenue $517.1M (+16% YoY); GAAP net income $66.4M; adjusted EBITDA $142.5M; operating cash $136.3M.
- Ended 2025 with $412.9M cash; plans to launch Prosigna LDT and TrueMRD test in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410126000008/0001384101-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410126000008/vcyt-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001384101-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer